• 01 Pipeline Progress
• 02 Technology Platform
• 03 Research Areas

Creating Value Through Innovation

Stable Cash Flow Supports The Innovation Pipeline

Pursuit of excellence, striving to make good medicines available sooner

Pipeline Progress

• Bogutai®
• UOS003
• Uni-GLP-1
• UDS003
• UB101/UB102
• UB104
• Fibronectin
• Beauty peptides
• Collagen
• Microecological skin-care
• Stem cell exosome
• Diquafosol sodium eye drop

Explore more

Formulation Integration Platform

Ensuring Fast Return-On-Investment

Integration and optimization, throughout the whole cycle, the pursuit of establishing a high-quality platform system

Technology Platform

• New Drug Research Platform
• Clinical Development Platform
• Production & Quality Platform
• Commercialization Platform

Explore more

Four-Wheel Drive

Focus On Multiple Critical Disease Areas

Differentiated layout, directly hit the pain points, capture the strong market potential

Research Areas

• Endocrinology (diabetes, osteoporosis, etc.)
• Ophthalmology (corneal injury, dry eye, AMD, DME, etc.)
• Skin care (wound healing, medical aesthetic advanced raw materials, etc.)

Explore more

Creating Value Through Innovation

Stable Cash Flow Supports The Innovation Pipeline

Pursuit of excellence, striving to make good medicines available sooner

Pipeline Progress

• 1、Bogutai®
• 2、UOS003
• 3、Uni-GLP-1
• 4、UDS003
• 5、UB101/UB102
• 6、UB104
• 7、Fibronectin
• 8、Beauty peptides
• 9、Collagen
• 10、Microecological skin-care
• 11、Stem cell exosome
• 12、Diquafosol sodium eye drop

Explore more

Formulation Integration Platform

Ensuring Fast Return-On-Investment

Integration and optimization, throughout the whole cycle, the pursuit of establishing a high-quality platform system

Technology Platform

• 1、New Drug Research Platform
• 2、Clinical Development Platform
• 3、Production & Quality Platform
• 4、Commercialization Platform

Explore more

Four-Wheel Drive

Focus On Multiple Critical Disease Areas

Differentiated layout, directly hit the pain points, capture the strong market potential

Research Areas

• 1、Endocrinology (diabetes, osteoporosis, etc.)
  2、Ophthalmology (corneal injury, dry eye, AMD, DME, etc.)
  3、Skin care (wound healing, medical aesthetic advanced raw materials, etc.)

Explore more

Caring, Responsible, Leading, Focused

Follow our promise “Leading genuine innovation”

Uni-Bio Science is committed to improving the quality of life of patients through innovative therapies and is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions, and has achieved several major milestones with its product portfolio and experienced commercial function.

2024-03-28

Uni-Bio Science Announces 2023 Annual Results

Record-breaking Revenue of HK$484.7M and Net Profit of HK$70.9M，Pioneering Breakthroughs in Osteoporosis, Medical Aesthetics, and Ophthalmology Markets

See More

2024-01-23

Marketing application of Diquafosol Sodium eye drops has been officially accepted by the China National Medical Products Administration (NMPA)

Uni-Bio Science Group Limited is pleased to announce the acceptance of its marketing application for Diquafosol Sodium eye drops by the China National Medical Products Administration (“NMPA”) on 23 January 2024, with the acceptance number “CYHS2400318“.

See More

2024-01-22

As A Breakthrough Drug For The Expansive Osteoporosis Market, Bogutai® (Teriparatide Injection) Has Been Officially Approved By The China National Medical Products Administration (NMPA)

Uni-Bio Science Group Limited is excited to announce that the China National Medical Products Administration ("NMPA") has officially approved the marketing application for BOGUTAI® (teriparatide injection) on January 16, 2024. This significant milestone h

See More

2023-08-29

Uni-Bio Science 2023 Interim Results，Achieved Record High Profit of HK$39.4M

Uni-Bio Science 2023 Interim Results，Achieved Record High Profit of HK$39.4M，Driven by Scale-Up Operations and Remarkable Growth in Marketed Drugs，Expanding Multiple Channels and Diverse Commercialization for New Products

See More